-
This is the second of a two-part series on switching to a five-level triage system. This month, well cover effective strategies to avoid problems during the transition.
-
Are you ever tempted to tell a patient with a sore throat who comes to your ED on a busy Saturday night that hell most likely be there in the morning, still waiting to be seen? What about if a woman with a headache asks you if shell make it home in time to pick up the kids at school and you take one look at the crowded waiting room and know the answer is no?
-
Have you pictured accreditation surveyors interviewing your newest, least well-spoken nurse about your restraint policy, as part of the new Shared Visions, New Pathways survey process that began in January 2004? Or have you envisioned patient tracers being done for an ED patient where everything that could go wrong, did?
-
Critical care patients being held in your ED for hours at a time are probably a familiar sight. Youre probably aware of the increased patient care needs these patients have, such as additional monitoring and assessment. But there is another factor putting these patients at risk: The chance of severe injury or death during transport for diagnostic tests such as computed tomography (CT) scans and magnetic resonance imaging (MRI).
-
Here is a listing of the supplies contained in the drug and airway boxes carried by ED nurses transporting patients for diagnostic tests at McKay Dee Hospital in Ogden, UT.
-
-
-
Women who initially were diagnosed with Stage IA disease and who had serous borderline tumors or underwent cystectomy appeared to derive the most benefit from restaging surgery. Nonetheless, the indications for restaging surgery remain controversial, as no difference in recurrence rate was observed between women who underwent restaging and those who did not.
-
The loss of heterozygosity in the tumor tissue of carriers coupled with the high frequency of patient and family history of breast and ovarian malignancies suggest that USPC might be part of the manifestation of familial breast-ovarian cancer in Ashkenazi Jews.
-
Positive Alendronate Data in Osteoporosis; NSAIDs For Myocardial Infarction; Four-Hour Window for CAP Patients; FDA Actions.
